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Abstract
Parkinson’s disease has multiple detrimental effects on motor and cognitive systems in the 
brain. In contrast to motor deficits, cognitive impairments in Parkinson’s disease are usually 
not ameliorated, and can even be worsened, by dopaminergic treatments. Recent evidence has 
shown potential benefits from restoring other neurotransmitter deficits, including 
noradrenergic and serotonergic transmission. Here, we study global and regional brain 
network organization using task-free imaging (also known as resting-state), which minimizes 
performance confounds and the bias towards predetermined networks. Thirty-three patients 
with idiopathic Parkinson’s disease were studied three times in a double-blind, placebo-
controlled counter-balanced crossover design, following placebo, 40mg-oral atomoxetine 
(selective noradrenaline reuptake inhibitor) or 30mg-oral citalopram (selective serotonin 
reuptake inhibitor). Neuropsychological assessments were performed outside the scanner. 
Seventy-six controls were scanned without medication to provide normative data for 
comparison to the patient cohort. Graph theoretical analysis of task-free brain connectivity, 
with a random 500-node parcellation, was used to measure the effect of disease in placebo-
treated state (versus unmedicated controls) and pharmacological intervention (drug versus 
placebo). Relative to controls, patients on placebo had executive impairments (reduced 
fluency and inhibitory control), which was reflected in dysfunctional network dynamics in 
terms of reduced clustering coefficient, hub degree and hub centrality. In patients, 
atomoxetine improved fluency in proportion to plasma concentration (p=0.006, r2=0.24), and 
improved response inhibition in proportion to increased hub eigen centrality (p=0.044, 
r2=0.14). Citalopram did not improve fluency or inhibitory control, but its influence on 
network integration and efficiency depended on disease severity: clustering (p=0.01, 
r2=0.22), modularity (p=0.043, r2=0.14) and path length (p=0.006, r2=0.25) increased in 
patients with milder forms of Parkinson’s disease, but decreased in patients with more 
advanced disease (UPDRS-III >30). This study supports the use of task-free imaging of brain 
networks in translational pharmacology of neurodegenerative disorders. We propose that hub 
connectivity contributes to cognitive performance in Parkinson’s disease, and that 
noradrenergic treatment strategies can partially restore the neural systems supporting 
executive function.  
https://mc.manuscriptcentral.com/braincom
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Introduction
Parkinson’s disease is characterized by its movement disorder but can also cause mild-to-
severe cognitive deficits which often involve impaired executive control. Dopaminergic 
therapies have limited efficacy for the treatment of cognitive changes in Parkinson’s disease 
and may even worsen impulsivity (Cools et al., 2003; Voon et al., 2006; Weintraub et al., 
2006). To restore cognitive function, an alternative approach is to target the deficits in 
noradrenergic transmission (Williams-Gray et al., 2007; Robbins and Arnsten, 2009; Vazey 
and Aston-Jones, 2012; Kehagia et al., 2014; Ye et al., 2015) and serotonergic transmission 
(Harrison et al., 1999; Fletcher et al., 2007). 
The primary source of forebrain noradrenaline is the locus coeruleus nucleus in the brainstem 
(Aston-Jones and Cohen, 2005), which is also an early site of pathology in Parkinson’s disease 
(Braak et al., 2003). This suggests that the noradrenergic system is a potential target for 
therapeutic intervention. The drug atomoxetine is a noradrenaline reuptake inhibitor which 
increases noradrenaline levels in the prefrontal cortex (Bymaster et al., 2002) and 
noradrenaline transporter occupancy (Seneca et al., 2006). Atomoxetine facilitates attentional 
set-shifting in preclinical studies (Newman et al., 2008) and improves response inhibition in 
preclinical models (Robinson et al., 2007) and healthy humans via modulation of prefrontal 
cortex activity (Chamberlain et al., 2009). In Parkinson’s disease, atomoxetine improves 
behavioural performance in a subgroup of patients, including enhanced response inhibition in 
relation to increased prefrontal cortex activity and fronto-striatal connectivity (Kehagia et al., 
2014; Ye et al., 2015; Rae et al., 2016). 
Serotonin has also been implicated in the cognitive deficits associated with Parkinson’s disease, 
and executive functions mediated by the prefrontal cortex (Rubia et al., 2005). The main source 
of forebrain serotonergic innervation is the raphe nuclei of the brainstem (Wilson and Molliver, 
1991). This is also an early site of neurodegeneration in Parkinson’s disease (Braak et al., 
2003), which impairs serotonergic transmission in the prefrontal cortex (Politis et al., 2010). 
Restoring serotonergic innervation is thus another potential target to improve the cognitive 
deficits in Parkinson’s disease. This notion is supported by a study showing that the serotonin 
reuptake inhibitor, citalopram, improves response inhibition in patients with moderate-to-
severe disease, in association with increased prefrontal activation (Ye et al., 2014). 
https://mc.manuscriptcentral.com/braincom
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Previous psychopharmacological imaging studies have assessed the effects of serotonin and 
noradrenaline reuptake inhibition on activity and connectivity during task performance. 
However, task-free (also known as resting-state) functional magnetic resonance imaging 
(fMRI) can be used to examine the effect of a drug on widespread brain network connectivity. 
Task-free fMRI allows for the inclusion of more diverse patients with significant cognitive and 
motor impairments while also minimizing task-related confounds, training demands and 
practice effects. It has been shown, for example, that noradrenaline influences fluctuations in 
brain network organization (van den Brink et al., 2016; van den Brink et al., 2018), and 
atomoxetine enhances prefrontal cortical connectivity in Parkinson’s disease in proportion to 
its effect on verbal fluency, a marker of executive function (Borchert et al., 2016).
The current study tested the hypotheses that the partial restoration of noradrenergic and 
serotonergic levels in Parkinson’s disease, via atomoxetine and citalopram respectively, 
restores brain network organization. To address this, we quantified the global and regional 
patterns of network integration and segregation using graph theoretical measures and compared 
these to indices of cognitive performance and disease severity. We tested two principal 
hypotheses: 1) Parkinson’s disease impairs whole-brain network function, quantified in terms 
of hub connectivity, modularity and centrality; and 2) treatment by atomoxetine and citalopram 
restores these functional brain network properties, in a subset of patients according to severity 
and drug level. 
Materials and Methods
Participants
Thirty-three Parkinson’s disease patients were recruited from the Cambridge University 
Parkinson’s disease Research Clinic according to United Kingdom Parkinson’s disease Society 
Brain Bank criteria. Seventy-six age- and sex-matched controls were recruited from the healthy 
volunteers registered with the Cambridge University Parkinson’s disease Research Clinic and 
the Medical Research Council’s Cognition and Brain Sciences Unit. Inclusion criteria were (i) 
right-handed; (ii) age 45-80 years; (iii) non-demented clinically and with Mini-Mental State 
Examination (MMSE) score >26/30; (iv) no clinically significant current depression; (v) no 
history of significant psychiatric disorder or epilepsy and (vi) no contraindications to MRI, 
atomoxetine or citalopram. None of the patients declared symptoms of impulse control 
disorders. The study was approved by the local research ethics committee with exemption from 
https://mc.manuscriptcentral.com/braincom
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clinical trials status by the United Kingdom Medicines for Human Use Regulatory Agency. All 
participants provided written consent.
Parkinson’s disease patients were administered the Unified Parkinson’s Disease Rating Scale 
motor subscale part III (UPDRS-III) on each study day, and all participants underwent 
cognitive assessment using the MMSE, digit span forward and backward, category and letter 
fluency (Rittman et al., 2013), the revised Beck-Depression inventory and a stop-signal 
reaction time task (SSRT). 
We anticipate that any potential future use of noradrenergic or serotonergic treatments targeting 
cognition in Parkinson’s disease would be adjunctive, and not an alternative, to standard 
dopaminergic therapy. Therefore, the effect of these drugs on patients was assessed in the 
context of their usual clinically optimized dopaminergic medication. Patients were not taking 
other directly serotonergic or noradrenergic medication, nor mono-amine-oxidase inhibitors. 
Levodopa Equivalent Dose (LED) was estimated (Tomlinson et al., 2010)  and included as a 
covariate in the analysis. 
Experimental design
A randomized double-blinded placebo-controlled crossover design was used for patient 
treatment by atomoxetine, citalopram and placebo. Patients underwent three separate sessions, 
at least six days apart at approximately the same time of day, consisting of cognitive and 
neurological assessments and brain imaging. The drug order was counter-balanced using 
permutation within groups of six successive subjects to reduce session-order effects on the drug 
effect. One patient participated in the control and atomoxetine sessions but not the citalopram 
session. Each patient received a 40mg oral dose of atomoxetine, a 30mg oral dose of citalopram 
or a placebo capsule at the start of each session. Drug plasma concentrations were measured 
and patients were scanned 2 hours after administration to coincide with peak plasma 
concentration for atomoxetine (Sauer et al., 2005) and citalopram (Sangkuhl et al., 2011). 
Controls were scanned once without drug or placebo to provide normative data. Note that the 
effect of disease (patient on placebo vs control) is confounded by potential placebo effects. The 
principal analysis of interest was the main effect of drug treatment within the patient group. 
https://mc.manuscriptcentral.com/braincom
D
ow
nloaded from
 https://academ
ic.oup.com
/braincom
m
s/advance-article-abstract/doi/10.1093/braincom
m
s/fcz013/5564114 by guest on 20 Septem
ber 2019
P a g e  | 6
fMRI data acquisition and pre-processing
Task-free functional imaging was performed at rest using a TIM-Trio 3T MRI scanner 
(Siemens Medical Systems, Erlangen, Germany). A minimum of 145 volumes were acquired 
using an echo-planar imaging (EPI) sequence (repetition time (TR) 2000ms, echo time (TE) 
30ms, matrix=64 × 64, in-plane resolution of 3 × 3mm, 32 slices of 3mm thickness with a 
0.75mm interslice gap, and a flip angle (FA) of 78°). Structural Magnetization-Prepared Rapid 
Acquisition with Gradient Echo (MPRAGE) scans (TR of 2300ms, TE of 2.86ms, matrix=192 
× 192, in-plane resolution of 1.25 × 1.25mm, 144 slices of 1.25mm thickness, inversion time 
of 900ms and FA of 9°) were also acquired during the same session.
In order to account for atrophy and in-scanner head movements, a pre-processing pipeline 
optimized for older subjects was used (Patel et al., 2014). We used a study-specific template 
generated from the MPRAGE images using the Diffeomorphic Anatomical Registration 
Through Exponentiated Lie Algebra (DARTEL) algorithm (Ashburner, 2007). Structural 
images were segmented and grey and white matter images from all participants were iteratively 
warped together over six steps to create the study-specific template which was then affine 
transformed to MNI space. 
Functional images were pre-processed using a customized version of the brainwavelet toolbox. 
Pre-processing steps included removal of the first five volumes, coregistration of the mean EPI 
image to the T1 image, transformation of the coregistered EPI to MNI space using the flow 
fields generated by the DARTEL algorithm, slice-timing correction, combined regression of 
cerebrospinal fluid signal and motion derivatives, high-pass band filter (0.01Hz) and wavelet 
despiking (Patel et al., 2014).
We combined approaches to minimize in-scanner head movement-related effects on the blood 
oxygen level-dependent (BOLD) signal. Wavelet despiking was used to despike movement-
related non-stationary events on a voxel level. Participants were excluded based on the average 
root mean-squared (RMS) displacement computed from the translation parameters of head 
motion: average RMS displacement over 2 standard deviations (SD) from the mean and/or 2 
SDs from the mean difference between placebo and drug sessions for patients. 
https://mc.manuscriptcentral.com/braincom
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Graph analysis
Graph theoretical analysis was used to investigate the characteristics of brain network 
organization. In the context of the brain, networks are composed of nodes, which represent 
brain regions, and edges, which represent the connectivity between the regions. Nodes were 
identified using a random 500-node parcellation to create nodes of approximately equal size. 
Nodes that were not sufficiently covered in ten participants or more were excluded (n=27). 
Wavelet correlations were used to generate association matrices (Achard et al., 2006). To 
generate binary graphs, local thresholds were applied (Alexander-Bloch et al., 2010) with 
thresholds between 1-10%. An intermediate density of 6% was used for primary statistical 
analysis (Cope et al., 2018). The graphs were Fisher-z transformed to normalize the correlation 
coefficients. A correction for multiple comparisons was not applied as network measures are 
not independent (Rittman et al., 2019).
The Maybrain toolbox (https://github.com/RittmanResearch/maybrain) was used to compute 
the three main topological properties of the networks using the correlation matrices: (1) Path 
length is the average shortest path length in a network and provides a measure of the efficiency 
of network-wide communication. (2) Clustering coefficient is a measure of the extent to which 
a node’s neighbours are inter-connected and provides insight into the local efficiency of a 
network. The organization of functional connectivity in the brain is similar to that of a small-
world network which is characterized by low path length and high clustering coefficient, 
creating an efficient network architecture with low connection cost (Latora and Marchiori, 
2003). (3) Modularity reflects the functional divisions of brain networks into clusters which 
are densely intra-connected and more sparsely inter-connected. 
Hub metrics
Hubs are highly connected nodes and their function is vital for information processing in a 
small-world network (Heuvel and Sporns, 2013; Stam, 2014). The functional significance of 
these hubs was quantified by computing the number of nodes connected to the hub node 
(degree) and the extent to which the hub node is central to information processing within the 
network. Hub regions were defined as nodes with a connection strength over 1.5 SDs above 
the mean in a randomly selected cohort consisting of half of the control participants (n=37). 
These nodes were used to compare hub metrics (degree, closeness centrality, betweenness 
centrality, eigen centrality) in the other half of the controls, not used for hub identification 
(n=38), to the patient placebo group (n=30). Hub metrics were then compared in patients 
https://mc.manuscriptcentral.com/braincom
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between no drug and drug sessions to determine if atomoxetine and/or citalopram modulated 
hub connectivity. 
Statistical analysis
Normative brain network graph metrics were quantified and compared between controls and 
patient placebo group, using two-sample t-tests. Outlier participants beyond 2 SDs from the 
mean were removed prior to analysis. The effect of drug on network connectivity was 
investigated using a repeated-measures ANOVA for graph measures in patients. Measures of 
age, UPDRS-III, LED (Tomlinson et al., 2010), change in neuropsychological performance on 
drug vs no drug and drug plasma concentration were included as covariates to investigate 
interactions between patient demographic/clinical characteristics and the effects of 
atomoxetine and citalopram on network connectivity.
Data availability
The terms of original participant consent prevent Open Access to raw data or other personally 
identifiable data but we would welcome requests from potential academic collaborators 
(please contact the senior author), while summary data and derived images may be requested 
from the corresponding author.
Results
After exclusions, the data from 75 controls and 30 patients (atomoxetine condition: n=30, 
citalopram condition n=29) were carried forward for analysis. Patient demographic and 
neuropsychological information are shown in Table 1. Controls and patients were matched for 
sex, age and education. Relative to controls, patients had lower MMSE and category fluency 
scores and longer stop-signal reaction times as expected.  
Eleven nodes in the graph had a degree over 1.5 SDs from the mean in the randomly selected 
control cohort (n=37) and were designated as hub nodes. The regions of these hub nodes are 
listed in Table 2, with numerical labelling according to the Automated Anatomical Labeling 
(AAL) atlas.
https://mc.manuscriptcentral.com/braincom
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Controls vs patients on placebo
There was no significant difference in path length or modularity between controls and patients 
on placebo. However, patients on placebo had lower clustering coefficient (p=0.038), hub 
degree (p=0.0001), hub betweenness centrality (p=0.009), hub closeness centrality (p=0.032) 
and hub eigen centrality (p=0.02).  
Effect of atomoxetine in patients
Within the patient group, peak plasma concentration of atomoxetine correlated with change in 
category fluency on the drug; patients with higher plasma concentrations demonstrated greater 
improvement (p=0.006, r2=0.24) (Fig. 1).
There was no significant main effect of atomoxetine on global clustering coefficient, path 
length, or modularity, relative to placebo. There was also no interaction between the effect of 
atomoxetine on these global graph metrics and covariates of interest. Lower baseline hub 
metrics correlated with a greater increase in the respective metric with atomoxetine towards 
controls for hub betweenness centrality (p=0.022, r2=0.17), hub closeness centrality (p<0.0005, 
r2=0.47) and hub eigen centrality (p=0.01, r2=0.21). Behavioural inhibition on a stop-signal 
task improved in patients on atomoxetine in proportion to baseline eigen centrality (p=0.025, 
r2=0.17) and increased hub eigen centrality on the drug (p=0.044, r2=0.14) (Fig. 2). 
Effect of citalopram in patients
Citalopram did not change fluency or inhibitory control at the group level or in proportion to 
plasma concentration. Lower baseline graph metrics correlated with a greater increase on 
citalopram towards controls in the respective metric for clustering coefficient (p=0.031, 
r2=0.16), modularity (p=0.036, r2=0.15), hub degree (p<0.0005, r2=0.59), hub betweenness 
centrality (p<0.0005, r2=0.76) and hub closeness centrality (p<0.0005, r2=0.57). Citalopram 
decreased clustering coefficient (p=0.01, r2=0.22), path length (p=0.006, r2=0.25) and 
modularity (p=0.043, r2=0.14) (Fig. 3) in proportion to disease severity (higher UPDRSIII 
scores). Citalopram did not alter group-wise global or hub metrics.  
https://mc.manuscriptcentral.com/braincom
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Discussion
This study reinforces the potential for noradrenergic reuptake inhibition (by atomoxetine) to 
improve brain network function in Parkinson’s disease, aimed at improving executive function. 
The potential for a serotonergic therapeutic effect depends on the severity of disease, as 
measured clinically by the UPDRS-III. These drug effects are set in the context of the impact 
of Parkinson’s disease on brain network function including the reduction of hub connectivity, 
and network modularity and centrality. 
The task-free fMRI encompassed both motor and cognitive networks. Although the loss of 
task-specificity may be seen as a disadvantage, the task-free approach has many advantages, 
including the minimization of performance confounds and practice effects in crossover designs; 
the scalability across severity levels, sites and languages in multicentre studies; and 
quantification of connectivity in nodes across several networks. It has revealed commonalities 
across many degenerative disorders in terms of network reorganization and hub connectivity 
in particular (Crossley et al., 2014). This makes it well suited to study a heterogeneous disorder 
such as Parkinson’s disease, with its motor and cognitive impairments (Williams-Gray et al., 
2013; Yarnall et al., 2014). 
In addition to the intrinsic heterogeneity of Parkinson’s disease, an oral dose of drug leads to 
widely differing plasma levels between individuals (Ye et al., 2015). This means that a single 
dose may not be equally effective in all patients and simple group-wise comparisons are likely 
to produce null findings. This is also true for dopaminergic effects on non-motor functions 
(Rowe et al., 2008; Cools et al., 2009) but it places particular emphasis on the need for 
predictive models of response, or at least stratification tools for future clinical trials. In this 
exploratory study however, we sought to explain changes in the effect of drug in relation to 
drug levels and disease severity. 
For atomoxetine, the change in fluency correlated with drug plasma concentration. Previous 
authors have suggested the relationship between atomoxetine concentration and task 
performance follows a Yerkes-Dodson “inverted U-shaped” function (Aston-Jones and Cohen, 
2005; Bari and Aston-Jones, 2013) which is influenced by baseline noradrenergic levels. For 
example, an individual with relatively higher baseline noradrenergic levels may overshoot the 
range for optimal performance if treated with atomoxetine (Housden et al., 2011). Atomoxetine 
administration in mild disease with presumed relatively intact endogenous noradrenaline 
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systems was detrimental, indicative of an ‘overdose’, placing noradrenaline beyond its optimal 
range (Ye et al., 2015). Here, we examined the effect of atomoxetine on verbal fluency, as both 
a marker of executive function and as a significant predictor of cognitive decline (Williams-
Gray et al., 2007). Atomoxetine plasma concentration and the change in fluency were 
correlated. A similar linear relationship was identified between atomoxetine plasma 
concentration and improvement on a task of problem-solving and working memory (Kehagia 
et al., 2014). We did not observe a direct relationship between atomoxetine plasma 
concentration and inhibitory control (the SSRT). However, there was an indirect relationship, 
expressed in terms of the effect of atomoxetine on hub eigen centrality and the effect of 
atomoxetine on inhibitory control. The effects of atomoxetine on different cognitive domains 
may be a feature of their different noradrenergic ‘optima’ or the differential degrees of 
neurodegeneration in neural circuits serving each cognitive domain (Rowe and Rittman, 2016; 
Haber, 2003; Rowe et al., 2008). In addition to plasma concentration, disease severity and the 
extent of noradrenergic denervation also influence response to atomoxetine in these patients. 
Noradrenaline is significantly reduced in the brain of Parkinson’s disease patients (Goldstein 
et al. 2015) and correlates with motor disease severity (Marie et al. 1995). Previous work has  
demonstrated that the effect of atomoxetine on fronto-striatal effective connectivity (Rae et al. 
2016) and stop-related inferior frontal gyrus activation (Ye et al. 2015) depends on disease 
severity. Hence, we suggest that both plasma concentration and noradrenergic denervation, 
indexed by disease severity, contribute to drug response in these patients.
Considering the widespread noradrenergic and serotonergic projections which are 
compromised in Parkinson’s disease, we predicted an effect of atomoxetine and citalopram on 
global network topology. Highly connected hub regions are preferentially affected in 
Parkinson’s disease, as well as other neurodegenerative diseases (Crossley et al., 2014), and 
loss of hub connectivity, particularly in the prefrontal cortex, has been linked to executive 
dysfunction (Rittman et al., 2016). Although atomoxetine did not significantly alter whole-
brain graph measures, it did change hub connectivity. Patients with increased hub eigen 
centrality on atomoxetine demonstrated improved inhibitory control in terms of the stop-signal 
task performance recorded outside the scanner. These improvements in behavioural inhibition 
and hub eigen centrality on atomoxetine were seen in patients with lower baseline hub eigen 
centrality on placebo. The stop-signal task elicits activation of the prefrontal cortex, 
particularly the right inferior frontal gyrus and pre-supplementary motor area (Garavan et al., 
1999; Aron et al., 2003; Rubia et al., 2003; Eagle et al., 2008; Rae et al., 2015). Improved 
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inhibitory control following atomoxetine administration is mediated by inferior frontal gyrus 
activity and its connectivity through the basal ganglia in Parkinson’s disease (Ye et al., 2015; 
Borchert et al., 2016; Rae et al., 2016), and healthy adults (Chamberlain et al., 2009). In our 
study, the change in connectivity of hubs correlated with improved SSRT on atomoxetine: 
these hub regions overlapped with those known to associate with response inhibition. 
Previous studies of citalopram in healthy volunteers found reduced task-free functional 
connectivity following drug administration (McCabe and Mishor, 2011; Schaefer et al., 2014; 
Klaassens et al., 2017). In the context of depression, these authors hypothesized that citalopram 
acted by normalizing functional connectivity. In Parkinson’s disease there is also a disruption 
of serotonergic transmission (Politis and Niccolini, 2015) which progresses over time (Politis 
et al., 2010), including regions of prefrontal cortex that are closely associated with inhibitory 
control, learning and cognitive flexibility, not only affective cognition. For example, the 
behavioural effects of serotonergic manipulations on response inhibition are mediated by the 
prefrontal cortex (Del-Ben et al., 2005; Macoveanu et al., 2013). Here, we found that improved 
clustering coefficient, modularity and hub connectivity on citalopram were associated with 
lower baseline values for these metrics. However, these measures were not associated with any 
change in cognitive performance on the drug. We previously reported that the benefit of 
citalopram on response inhibition and an associated neural activation emerged only in patients 
with more advanced disease, especially if they had relatively preserved fronto-striatal 
connectivity (Ye et al., 2014). In the current analysis, the effect of Parkinson’s disease was to 
reduce the brain’s clustering coefficient and centrality measures.  If this were primarily due to 
serotonergic impairments, we would expect that citalopram would increase these network 
properties towards a normal level with more severe disease. However, despite a modest positive 
effect on connectivity in patients with mild disease, this declined with disease severity. In other 
words, patients with more severe disease appeared resistant to the effect of citalopram on the 
topology of brain network organization. This was unexpected and could be the result of altered 
response to citalopram due to significant degeneration in the more severely affected patients. 
Serotonergic transmission is disrupted in Parkinson’s disease and the extent of denervation 
progresses with disease severity (Politis et al., 2010; Politis and Niccolini, 2015). An impaired 
serotonergic architecture could explain the resilience of global and hub metrics to citalopram 
in more advance disease. We speculate that our findings result from the heterogeneity of the 
effects of Parkinson’s disease and variable sites of action of citalopram, leading to a null effect 
on global measures in patients with severe disease, in contrast to the previously reported effects 
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on focal prefrontal cortical activations (Ye et al., 2014).  Future investigations using 7T-MRI 
of the locus coeruleus (Betts et al., 2019), PET imaging of serotonergic receptor density or 
noradrenaline transporter density, or SPECT imaging of dopamine transporter, could provide 
further insight into the relationship between drug response and the integrity of noradrenergic, 
dopaminergic and serotonergic systems.
This study had several limitations. First, although patients received one dose of atomoxetine or 
citalopram during brain imaging, chronic drug administration may differentially affect 
cognitive and functional connectivity (Koda et al., 2010). This could be mediated by down-
regulation of neurotransmitter receptors or synthesis and future studies should investigate the 
effect of chronic drug treatment. Second, BOLD signals could have been influenced by 
atomoxetine, citalopram and/or dopaminergic drugs. However, this is unlikely as cerebral 
blood flow remains normal following atomoxetine (Marquand et al., 2012) and citalopram 
(Macoveanu et al., 2013) administration, and dopaminergic therapy was kept constant in the 
within-subject crossover analyses. Although the non-trial medication was kept constant as part 
of patients’ standard therapy in the drug vs placebo comparison, this was not controlled for 
when comparing patients on placebo to healthy controls. Indirect effects of placebo treatment 
on cognitive or neurotransmitter systems confound the comparison of patients with controls in 
this study. However, this caveat does not affect the comparison of drug vs placebo in patients. 
Third, the mediating effect of atomoxetine on functional connectivity has several potential 
contributory mechanisms. Atomoxetine can affect dopaminergic as well as noradrenergic 
transmission (Bymaster et al., 2002). However, effects of atomoxetine on response inhibition 
have been shown to be primarily mediated by noradrenergic transmission in animal studies 
(Bari et al., 2009). 
In conclusion, atomoxetine and citalopram modulate resting-state functional connectivity in 
Parkinson’s disease in different ways. We suggest that hub connectivity mediates the effect of 
atomoxetine on executive function while citalopram alters whole-brain graph metrics 
according to disease severity. This study provides support for the use of task-free imaging 
methods to assess the impact of drugs on neurocognitive systems in patients.
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Table 1: Participant clinical, cognitive and demographic characteristics at baseline before 
trial medication. Groups are compared by unpaired t-test or chi-squared test as appropriate. 
Patients 
Mean (SD)
Controls 
Mean (SD)
Difference      
(p-value)
Male:Female 19:11 41:34 ns
Age (years) 67(7.3) 67.1(8.4) ns
Education (years) 14.2(3.6) 14.8(4.0) ns
MMSE 28.4(1.7) 29.2(1.1) 0.009
Disease duration 
(years)
10.5(4.4) - -
LED (mg/day) 870(469) - -
UPDRS III ‘on’ 22.6(6.8) - -
Category fluency 18.3(5.5) 24.3(6.2) 0.0001
Letter fluency 16.0(4.4) 18.3(5.7) ns
Digit Span Forward 7.0(1.1) 7.3(0.8) ns
Digit Span Backward 5.5(1.2) 6.0(1.3) ns
Stop-signal reaction 
time (ms)
198(73) 164(39) 0.02
Atomoxetine plasma 
concentration (ng/mL)
372.1(167.4) - -
Citalopram plasma 
concentration (ng/mL)
35.6(14.7) - -
Table 2: Hub node regions used for analysis 
AAL 
label
AAL region
84 Right superior temporal pole
91 Left crus I of cerebellar hemisphere
81 Left superior temporal gyrus
83 Left superior temporal pole
10 Right middle frontal gyrus, orbital part
78 Right thalamus
34 Right midcingulate area
55 Left fusiform gyrus
100 Right lobule VI of cerebellar hemisphere
16 Right inferior frontal gyrus, pars orbitalis
90 Right inferior temporal gyrus
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Figure 1.  Atomoxetine plasma concentrations.  Patients with higher peak plasma 
concentrations of atomoxetine demonstrated greater improvement in category fluency 
(measured by number of words produced in a category) on the drug relative to placebo 
(p=0.006, r2=0.24).
 
Figure 2. Hub centrality on atomoxetine. Patients with increased hub eigen centrality on 
atomoxetine had faster stop-signal reaction times (ms) on the drug (p=0.044, r2=0.14).
Figure 3. Network connectivity on citalopram. Citalopram decreased (a) clustering 
coefficient (p=0.01, r2=0.22), (b) path length (p=0.006, r2=0.25) and (c) modularity (p=0.043, 
r2=0.14) in Parkinson’s disease patients with higher UPDRSIII scores.
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